Amanote Research
Register
Sign In
P067 Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritisand Psoriatic Arthritis
doi 10.1136/annrheumdis-2018-ewrr2019.56
Full Text
Open PDF
Abstract
Available in
full text
Date
March 1, 2019
Authors
V Marzaioli
M Canavan
A Floudas
S Wade
C Low
DJ Veale
U Fearon
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Related search
Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis
Expert Review of Clinical Immunology
Allergy
Immunology
SAT0439 Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
P171 Hsp90 in Axial Spondyloarthritis, Psoriatic Arthritis and Rheumatoid Arthritis
Tofacitinib: A Janus Kinase Inhibitor for Rheumatoid Arthritis
Prescriber
Pharmacology
Experience With Tofacitinib in the Treatment of Resistant Rheumatoid Arthritis
Modern Rheumatology Journal
Monocyte Chemotactic Factor in Rheumatoid Arthritis Synovial Tissue
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
P133 Clinical and Immunological Effects of Tofacitinib Therapy in Rheumatoid Arthritis
Psoriatic Spondylitis in a Patient With Classical Rheumatoid Arthritis.
Postgraduate Medical Journal
Medicine
Maturation and Trafficking of Monocyte-Derived Dendritic Cells in Monkeys: Implications for Dendritic Cell-Based Vaccines
Journal of Immunology
Allergy
Immunology
